We wanted to draw attention to an interesting article published in the HBOTT Dec 2019 Newsletter.
Tysabri (natalizumab) is very effective for people with highly active relapsing remitting MS but it carries the risk of developing a rare but very serious brain infection called progressive multifocal leukoencephalopathy (PML).
Sativex, a cannabis based drug for MS related spasticity, has been approved by NICE as a cost effective treatment for the NHS in England.
The European Medicines Agency (EMA) has recommended that a licence should be granted for siponimod (Mayzent) for the treatment of active secondary progressive MS (SPMS).
East Kent leads the way in robotic trials to improve patients’ mobility. Patients from Scotland, Suffolk, London, Surrey, Essex and Berkshire are travelling to Kent to take part in a ground-breaking clinical trial at the Kent and Canterbury Hospital.